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BACKGROUND
The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in 
addition to standard care, on cardiovascular morbidity and mortality in patients 
with type 2 diabetes at high cardiovascular risk are not known.
METHODS
We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or 
placebo once daily. The primary composite outcome was death from cardiovascu-
lar causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the 
pooled empagliflozin group versus the placebo group. The key secondary compos-
ite outcome was the primary outcome plus hospitalization for unstable angina.
RESULTS
A total of 7020 patients were treated (median observation time, 3.1 years). The 
primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empa-
gliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard 
ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; 
P = 0.04 for superiority). There were no significant between-group differences in 
the rates of myocardial infarction or stroke, but in the empagliflozin group there 
were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% 
in the placebo group; 38% relative risk reduction), hospitalization for heart failure 
(2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any 
cause (5.7% and 8.3%, respectively; 32% relative risk reduction). There was no 
significant between-group difference in the key secondary outcome (P = 0.08 for 
superiority). Among patients receiving empagliflozin, there was an increased rate 
of genital infection but no increase in other adverse events.
CONCLUSIONS
Patients with type 2 diabetes at high risk for cardiovascular events who received 
empagliflozin, as compared with placebo, had a lower rate of the primary com-
posite cardiovascular outcome and of death from any cause when the study drug 
was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; 
EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.)
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Type 2 diabetes is a major risk factor for cardiovascular disease,1,2 and the pres-ence of both type 2 diabetes and cardio-
vascular disease increases the risk of death.3 
Evidence that glucose lowering reduces the rates 
of cardiovascular events and death has not been 
convincingly shown,4-6 although a modest cardio-
vascular benefit may be observed after a prolonged 
follow-up period.7 Furthermore, there is concern 
that intensive glucose lowering or the use of 
specific glucose-lowering drugs may be associat-
ed with adverse cardiovascular outcomes.8 There-
fore, it is necessary to establish the cardiovascu-
lar safety benefits of glucose-lowering agents.9
Inhibitors of sodium–glucose cotransporter 2 
reduce rates of hyperglycemia in patients with 
type 2 diabetes by decreasing renal glucose re-
absorption, thereby increasing urinary glucose 
excretion.10 Empagliflozin is a selective inhibitor 
of sodium glucose cotransporter 211 that has 
been approved for type 2 diabetes.12 Given as 
either monotherapy or as an add-on therapy, the 
drug is reported to reduce glycated hemoglobin 
levels in patients with type 2 diabetes, including 
those with stage 2 or 3a chronic kidney dis-
ease.13-20 Furthermore, empaglif lozin is associ-
ated with weight loss and reductions in blood 
pressure without increases in heart rate.13-20 
Empagliflozin also has favorable effects on mark-
ers of arterial stiffness and vascular resistance,21 
visceral adiposity,22 albuminuria,20 and plasma 
urate.13-19 Empaglif lozin has been associated 
with an increase in levels of both low-density 
lipoprotein (LDL)14 and high-density lipoprotein 
(HDL) cholesterol.13-16 The most common side 
effects of empagliflozin are urinary tract infec-
tion and genital infection.12
In the EMPA-REG OUTCOME trial, we exam-
ined the effects of empagliflozin, as compared 
with placebo, on cardiovascular morbidity and 
mortality in patients with type 2 diabetes at high 
risk for cardiovascular events who were receiv-
ing standard care.
Me thods
Study Oversight
The trial was designed and overseen by a steer-
ing committee that included academic investiga-
tors and employees of Boehringer Ingelheim. The 
role of Eli Lilly was limited to cofunding the trial. 
Safety data were reviewed by an independent aca-
demic data monitoring committee every 90 days 
or at the discretion of the committee. Cardiovas-
cular outcome events and deaths were prospec-
tively adjudicated by two clinical-events commit-
tees (one for cardiac events and the other for 
neurologic events), as recommended by the Food 
and Drug Administration (FDA) guidelines.9 A 
list of investigators and committee members is 
provided in Sections A and B, respectively, in the 
Supplementary Appendix, which is available with 
the full text of this article at NEJM.org.
The trial was conducted in accordance with 
the principles of the Declaration of Helsinki and 
the the International Conference on Harmonisa-
tion Good Clinical Practice guidelines and was 
approved by local authorities. An independent 
ethics committee or institutional review board 
approved the clinical protocol at each participat-
ing center. All the patients provided written in-
formed consent before study entry.
All the authors were involved in the study 
design and had access to the data, which were 
analyzed by one of the study sponsors, Boeh-
ringer Ingelheim. All the authors vouch for the 
accuracy and completeness of the data analyses 
and for the fidelity of the study to the protocol, 
available at NEJM.org. Members of the Univer-
sity of Freiburg conducted an independent statis-
tical analysis of cardiovascular outcomes (Section 
B in the Supplementary Appendix). The manu-
script was drafted by the first and last authors 
and revised by all the authors. Medical writing 
assistance, which was paid for by Boehringer 
Ingelheim, was provided by Fleishman-Hillard 
Group.
Study Design
As described previously,23 this was a randomized, 
double-blind, placebo-controlled trial to assess 
the effect of once-daily empagliflozin (at a dose 
of either 10 mg or 25 mg) versus placebo on 
cardiovascular events in adults with type 2 dia-
betes at high cardiovascular risk against a back-
ground of standard care. Patients were treated at 
590 sites in 42 countries. The trial continued 
until an adjudicated primary outcome event had 
occurred in at least 691 patients.
Study Patients
Eligible patients with type 2 diabetes were adults 
(≥18 years of age) with a body-mass index (the 
weight in kilograms divided by the square of the 
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height in meters) of 45 or less and an estimated 
glomerular filtration rate (eGFR) of at least 30 ml 
per minute per 1.73 m2 of body-surface area, ac-
cording to the Modification of Diet in Renal 
Disease criteria. All the patients had established 
cardiovascular disease (as defined in Section C 
in the Supplementary Appendix) and had received 
no glucose-lowering agents for at least 12 weeks 
before randomization and had a glycated hemo-
globin level of at least 7.0% and no more than 
9.0% or had received stable glucose-lowering 
therapy for at least 12 weeks before randomiza-
tion and had a glycated hemoglobin level of at 
least 7.0% and no more than 10.0%. Other key 
exclusion criteria are provided in Section D in 
the Supplementary Appendix.
Study Procedures
Eligible patients underwent a 2-week, open-la-
bel, placebo run-in period in which background 
glucose-lowering therapy was unchanged. Patients 
meeting the inclusion criteria were then ran-
domly assigned in a 1:1:1 ratio to receive either 
10 mg or 25 mg of empagliflozin or placebo once 
daily. Randomization was performed with the use 
of a computer-generated random-sequence and 
interactive voice- and Web-response system and 
was stratified according to the glycated hemo-
globin level at screening (<8.5% or ≥8.5%), body-
mass index at randomization (<30 or ≥30), renal 
function at screening (eGFR, 30 to 59 ml, 60 to 
89 ml, or ≥90 ml per minute per 1.73 m2), and 
geographic region (North America [plus Austra-
lia and New Zealand], Latin America, Europe, 
Africa, or Asia).
Background glucose-lowering therapy was to 
remain unchanged for the first 12 weeks after 
randomization, although intensification was per-
mitted if the patient had a confirmed fasting 
glucose level of more than 240 mg per deciliter 
(>13.3 mmol per liter). In cases of medical neces-
sity, dose reduction or discontinuation of back-
ground medication could occur. After week 12, 
investigators were encouraged to adjust glucose-
lowering therapy at their discretion to achieve 
glycemic control according to local guidelines. 
Throughout the trial, investigators were encour-
aged to treat other cardiovascular risk factors 
(including dyslipidemia and hypertension) to 
achieve the best available standard of care accord-
ing to local guidelines. Patients were instructed 
to attend the clinic at prespecified times, which 
included a follow-up visit 30 days after the end 
of treatment. Patients who prematurely discon-
tinued a study drug were to be followed for as-
certainment of cardiovascular outcomes, and 
attempts were made to collect vital-status infor-
mation for any patient who was lost to follow-up, 
as allowed by local guidelines.
Study Outcomes
The primary outcome was a composite of death 
from cardiovascular causes, nonfatal myocardial 
infarction (excluding silent myocardial infarc-
tion), or nonfatal stroke. The key secondary out-
come was a composite of the primary outcome 
plus hospitalization for unstable angina. Defini-
tions of the major clinical outcomes are provid-
ed in Section E in the Supplementary Appendix.
Safety was assessed on the basis of adverse 
events that occurred during treatment or within 
7 days after the last dose of a study drug and 
were coded with the use of the Medical Dictionary 
for Regulatory Activities, version 18.0. Adverse events 
of special interest included confirmed hypogly-
cemic adverse events (plasma glucose level, ≤70 mg 
per deciliter [3.9 mmol per liter] or an event re-
quiring assistance), and adverse events reflecting 
urinary tract infection, genital infection, volume 
depletion, acute renal failure, bone fracture, dia-
betic ketoacidosis, and thromboembolic events.
Statistical Analysis
The primary hypothesis was noninferiority for 
the primary outcome with empagliflozin (pooled 
doses of 10 mg and 25 mg) versus placebo with 
a margin of 1.3 for the hazard ratio.9 We used a 
four-step hierarchical-testing strategy for the 
pooled empagliflozin group versus the placebo 
group in the following order: noninferiority for 
the primary outcome, noninferiority for the key 
secondary outcome, superiority for the primary 
outcome, and superiority for the key secondary 
outcome.
Since interim data from the trial were included 
in a new-drug application submitted to the FDA, 
under the Haybittle–Peto rule, a two-sided P value 
of 0.0498 or less was considered to indicate sta-
tistical significance in the final analyses.23 For 
the test of noninferiority for the primary out-
come with a margin of 1.3 at a one-sided level of 
0.0249, at least 691 events were required to pro-
vide a power of at least 90% on the assumption 
of a true hazard ratio of 1.0. Noninferiority for 
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the primary outcome was determined if the up-
per boundary of the two-sided 95.02% confi-
dence interval was less than 1.3. Analyses were 
based on a Cox proportional-hazards model, with 
study group, age, sex, baseline body-mass index, 
baseline glycated hemoglobin level, baseline eGFR, 
and geographic region as factors. Estimates of 
cumulative-incidence function were corrected 
for death as a competing risk,24 except for death 
from any cause, for which Kaplan–Meier esti-
mates are presented. Because of the declining 
numbers of patients at risk, cumulative-inci-
dence plots have been truncated at 48 months. 
We calculated the number of patients who would 
need to be treated to prevent one death on the 
basis of the exponential distribution.
We performed the primary analysis using a 
modified intention-to-treat approach among pa-
tients who had received at least one dose of a 
study drug. Data for patients who did not have 
an event were censored on the last day they were 
known to be free of the outcome. Secondary 
analyses included comparisons of the 10-mg dose 
of empagliflozin versus placebo and the 25-mg 
dose versus placebo. Sensitivity analyses are de-
scribed in the Section F in the Supplementary 
Appendix. We analyzed the changes from base-
line in glycated hemoglobin level, weight, waist 
circumference, systolic and diastolic blood pres-
sure, heart rate, LDL and HDL cholesterol, and 
uric acid using a repeated-measures analysis as 
a mixed model. Subgroup analyses are described 
in Section F in the Supplementary Appendix.
R esult s
Study Patients
A total of 7028 patients underwent randomiza-
tion from September 2010 through April 2013. 
Of these patients, 7020 were treated and in-
cluded in the primary analysis (Fig. S1 in Section 
G in the Supplementary Appendix). Reasons for 
premature discontinuation are provided in Table 
S1 in Section H in the Supplementary Appendix. 
Overall, 97.0% of patients completed the study, 
with 25.4% of patients prematurely discontinu-
ing a study drug. Final vital status was available 
for 99.2% of patients.
At baseline, demographic and clinical charac-
teristics were well balanced between the placebo 
group and the empagliflozin group (Table S2 in 
Section I in the Supplementary Appendix). Ac-
cording to the inclusion criteria, more than 99% 
of patients had established cardiovascular dis-
ease, and patients were well treated with respect 
to the use of lipid-lowering therapy and antihy-
pertensive medications at baseline. The median 
duration of treatment was 2.6 years, and the 
median observation time was 3.1 years; both 
durations were similar in the pooled empa-
gliflozin group and the placebo group (Table S3 
in Section J in the Supplementary Appendix).
Cardiovascular Outcomes
The primary outcome occurred in a significantly 
lower percentage of patients in the empagliflozin 
group (490 of 4687 [10.5%]) than in the placebo 
group (282 of 2333 [12.1%]) (hazard ratio in the 
empagliflozin group, 0.86; 95.02% confidence 
interval [CI], 0.74 to 0.99; P<0.001 for noninferi-
ority and P = 0.04 for superiority) (Fig. 1A). The 
key secondary outcome occurred in 599 of 4687 
patients (12.8%) in the empagliflozin group and 
333 of 2333 patients (14.3%) in the placebo 
group (hazard ratio, 0.89; 95% CI, 0.78 to 1.01; 
P<0.001 for noninferiority and P = 0.08 for supe-
riority).
As compared with placebo, empagliflozin 
resulted in a significantly lower risk of death 
from cardiovascular causes (hazard ratio, 0.62; 
95% CI, 0.49 to 0.77; P<0.001) (Fig. 1B), death 
from any cause (hazard ratio, 0.68; 95% CI, 0.57 
to 0.82, P<0.001; Fig. 1C), and hospitalization 
for heart failure (hazard ratio, 0.65; 95% CI, 0.50 
to 0.85; P = 0.002) (Fig. 1D). Hazard ratios for 
cardiovascular outcomes with empagliflozin ver-
sus placebo are shown in Table 1. Absolute re-
ductions in incidence rates for cardiovascular 
outcomes are provided in Table S4 in Section K 
in the Supplementary Appendix. All categories 
of death from cardiovascular causes contributed 
to the reduction in cardiovascular death in the 
empagliflozin group (Table S5 in Section L in 
the Supplementary Appendix). There were no 
significant between-group differences in the oc-
currence of myocardial infarction or stroke (Ta-
ble 1). Myocardial infarction was reported in 
4.8% of patients in the empagliflozin group and 
5.4% of those in the placebo group, and stroke 
in 3.5% and 3.0% of patients, respectively.
For the primary and key secondary outcomes, 
hazard ratios for the comparison between the 
10-mg dose of empagliflozin versus placebo and 
the 25-mg dose versus placebo were virtually 
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identical to those in the pooled analysis, but the 
individual dose effects were not significant, ow-
ing to the smaller numbers of outcome events in 
the individual groups (Table S6 and Fig. S2 in 
Section M in the Supplementary Appendix). The 
hazard ratios for the primary outcome were 0.85 
(95% CI, 0.72 to 1.01; P = 0.07) for the 10-mg 
dose of empagliflozin versus placebo and 0.86 
(95% CI, 0.73 to 1.02; P = 0.09) for the 25-mg 
dose versus placebo.
In subgroup analyses, there was some hetero-
geneity for the primary outcome. In contrast, 
there was a consistent benefit of empagliflozin 
versus placebo on death from cardiovascular 
causes across all subgroups (Fig. 2, and Tables 
S7 and S8 in Section N in the Supplementary 
Appendix).
In prespecified sensitivity analyses based on 
events that occurred within 30 days after last 
dose of a study drug, results for the primary 
outcome, cardiovascular death, myocardial in-
farction, and stroke were consistent with the 
Outcome
Placebo 
(N = 2333)
Empagliflozin 
(N = 4687)
Hazard Ratio 
 (95% CI) P Value
no. (%)
rate/1000 
 patient-yr no. (%)
rate/1000 
 patient-yr
Death from cardiovascular causes, nonfatal myocar-
dial infarction, or nonfatal stroke: primary 
outcome*
282 (12.1) 43.9 490 (10.5) 37.4 0.86 (0.74–0.99)
Noninferiority <0.001†
Superiority 0.04†
Death from cardiovascular causes, nonfatal myo-
cardial infarction, nonfatal stroke, or hospi-
talization for unstable angina: key secondary 
outcome*
333 (14.3) 52.5 599 (12.8) 46.4 0.89 (0.78–1.01)
Noninferiority <0.001†
Superiority 0.08†
Death
From any cause 194 (8.3) 28.6 269 (5.7) 19.4 0.68 (0.57–0.82) <0.001
From cardiovascular causes 137 (5.9) 20.2 172 (3.7) 12.4 0.62 (0.49–0.77) <0.001
Fatal or nonfatal myocardial infarction excluding 
 silent myocardial infarction
126 (5.4) 19.3 223 (4.8) 16.8 0.87 (0.70–1.09) 0.23
Nonfatal myocardial infarction excluding silent 
myocardial infarction
121 (5.2) 18.5 213 (4.5) 16.0 0.87 (0.70–1.09) 0.22
Silent myocardial infarction‡ 15 (1.2) 5.4 38 (1.6) 7.0 1.28 (0.70–2.33) 0.42
Hospitalization for unstable angina 66 (2.8) 10.0 133 (2.8) 10.0 0.99 (0.74–1.34) 0.97
Coronary revascularization procedure 186 (8.0) 29.1 329 (7.0) 25.1 0.86 (0.72–1.04) 0.11
Fatal or nonfatal stroke 69 (3.0) 10.5 164 (3.5) 12.3 1.18 (0.89–1.56) 0.26
Nonfatal stroke 60 (2.6) 9.1 150 (3.2) 11.2 1.24 (0.92–1.67) 0.16
Transient ischemic attack 23 (1.0) 3.5 39 (0.8) 2.9 0.85 (0.51–1.42) 0.54
Hospitalization for heart failure 95 (4.1) 14.5 126 (2.7) 9.4 0.65 (0.50–0.85) 0.002
Hospitalization for heart failure or death from car-
diovascular causes excluding fatal stroke
198 (8.5) 30.1 265 (5.7) 19.7 0.66 (0.55–0.79) <0.001
*  Data were analyzed with the use of a four-step hierarchical-testing strategy for the pooled empagliflozin group versus the placebo group in 
the following order: noninferiority for the primary outcome, noninferiority for the key secondary outcome, superiority for the primary out-
come, and superiority for the key secondary outcome. Each successive hypothesis could be tested, provided that those preceding it met the 
designated level of significance. Data are based on Cox regression analyses in patients who received at least one dose of a study drug.
†  One-sided P values are shown for tests of noninferiority, and two-sided P values are shown for tests of superiority.
‡  Silent myocardial infarction was analyzed in 2378 patients in the empagliflozin group and 1211 patients in the placebo group.
Table 1. Primary and Secondary Cardiovascular Outcomes.
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primary analyses, and the point estimate for the 
hazard ratio for stroke was closer to 1.00 (Tables 
S9 and S10 in Section O in the Supplementary 
Appendix). A sensitivity analysis of death from 
any cause in which it was assumed that all pa-
tients who were lost to follow-up in the empa-
gliflozin group died and all patients who were 
lost to follow-up in the placebo group were alive 
showed a significant benefit of empagliflozin 
versus placebo (hazard ratio, 0.77; 95% CI, 0.65 
to 0.93; P = 0.005).
Glycemic Control
After 12 weeks, during which glucose-lowering 
therapy was to remain unchanged, the adjusted 
mean differences in the glycated hemoglobin 
level between patients receiving empaglif lozin 
and those receiving placebo were −0.54 percent-
age points (95% CI, −0.58 to −0.49) in the 10-mg 
group and −0.60 percentage points (95% CI, 
−0.64 to −0.55) in the 25-mg group (Fig. 3). At 
week 94, the adjusted mean differences in the 
glycated hemoglobin level between patients re-
ceiving empagliflozin and those receiving pla-
cebo were −0.42 percentage points (95% CI, 
−0.48 to −0.36) and −0.47 percentage points 
(95% CI, −0.54 to −0.41), respectively; at week 
206, the differences were −0.24 percentage 
points (95% CI, −0.40 to −0.08) and −0.36 per-
centage points (95% CI, −0.51 to −0.20).
Cardiovascular Risk Factors
Over the course of the study, empagliflozin, as 
compared with placebo, was associated with 
small reductions in weight, waist circumference, 
uric acid level, and systolic and diastolic blood 
pressure with no increase in heart rate and small 
increases in both LDL and HDL cholesterol (Fig. 
S3 in Section P in the Supplementary Appendix). 
A higher percentage of patients in the placebo 
group received additional glucose-lowering med-
ications (including sulfonylurea and insulin), 
antihypertensive medications (including diuret-
ics), and anticoagulants during the trial, with no 
between-group difference in the receipt of lipid-
lowering drugs (Tables S11 and S12 in Section Q 
in the Supplementary Appendix).
Safety and Adverse Events
The proportions of patients who had adverse 
events, serious adverse events, and adverse events 
leading to the discontinuation of a study drug 
were similar in the empagliflozin group and the 
placebo group (Table 2). Genital infection was 
reported in a higher percentage of patients in 
the pooled empagliflozin group. The propor-
tions of patients with confirmed hypoglycemic 
adverse events, acute renal failure, diabetic keto-
acidosis, thromboembolic events, bone fracture, 
and events consistent with volume depletion 
were similar in the two study groups. Urosepsis 
was reported in 0.4% of patients in the empa-
gliflozin group and 0.1% of those in the placebo 
group, but there was no imbalance in overall 
rates of urinary tract infection, complicated uri-
nary tract infection, or pyelonephritis (Table S13 
in Section R in the Supplementary Appendix). 
Clinical laboratory data are provided in Table 
S14 in Section S in the Supplementary Appendix. 
There were no relevant changes in electrolytes in 
the two study groups. Hematocrit values were 
higher in the empagliflozin groups than in the 
placebo group (mean [±SD] changes from base-
line, 4.8±5.5% in the group receiving 10 mg of 
empagliflozin, 5.0±5.3% in the group receiving 
25 mg of empagliflozin, and 0.9±4.7% in the 
placebo group).
Discussion
Among patients with type 2 diabetes at high risk 
for cardiovascular events, those receiving empa-
gliflozin had a lower rate of the primary com-
posite outcome of death from cardiovascular 
causes, nonfatal myocardial infarction, or non-
fatal stroke than did patients receiving placebo. 
The difference between empagliflozin and pla-
cebo was driven by a significant reduction in 
death from cardiovascular causes, with no sig-
nificant between-group difference in the risk of 
myocardial infarction or stroke. Since the two 
groups had similar rates of hospitalization for 
unstable angina, there was no significant differ-
ence in the key secondary outcome, which in-
cluded the risk of hospitalization for unstable 
angina. Patients in the empagliflozin group had 
significantly lower risks of death from any cause 
and for hospitalization for heart failure than did 
those in the placebo group.
Although a small dose–response effect for 
the 10-mg dose of empagliflozin versus placebo 
and the 25-mg dose versus placebo has been 
documented for metabolic responses, in our 
study the two dose groups had similar hazard 
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0.25 0.50 1.00 2.00 
Hazard Ratio
(95% CI) 
P Value for 
Interaction
Favors Placebo Favors Empagliflozin Favors Placebo Favors Empagliflozin 
0.50 0.25 1.00 2.00 
Hazard Ratio
(95% CI) 
 
All patients
Age
<65 yr
≥65 yr
Sex
Male
Female
Race
White
Asian
Black
Glycated hemoglobin
<8.5%
≥8.5%
Body-mass index
<30
≥30 
Blood pressure control
SBP ≥140 mm Hg or DBP ≥90 mm Hg
SBP <140 mm Hg and DBP <90 mm Hg
Estimated glomerular filtration rate
≥90 ml/min/1.73 m2
60 to <90 ml/min/1.73 m2
<60 ml/min/1.73 m2
Urine albumin-to-creatinine ratio
<30 mg/g
≥30 to 300 mg/g
>300 mg/g
Cardiovascular risk
Only cerebrovascular disease
Only coronary artery disease
Only peripheral artery disease
2 or 3 high-risk categories
Insulin
No
Yes
Statins or ezetimibe
No
Yes
Antihypertensive therapy
No
Yes
ACE inhibitor or ARB
No
Yes
Beta-blocker
No
Yes
Diuretic
No
Yes
Empagliflozin PlaceboSubgroup
4687
2596
2091
3336
1351
3403
1006
237
3212
1475
2279
2408
1780
2907
1050
2425
1212
2789
1338
509
635
2732
412
878
2435
2252
1029
3658
241
4446
889
3798
1631
3056
2640
2047
2333
1297
1036
1680
653
1678
511
120
1607
726
1120
1213
934
1399
488
1238
607
1382
675
260
325
1340
191
451
1198
1135
551
1782
112
2221
465
1868
835
1498
1345
988
0.01
0.81
0.09
0.01
0.06
0.65
0.20
0.40
0.53
0.28
0.54
0.80
0.49
0.61
0.72
P Value for 
Interaction
0.21
0.32
0.43
0.51
0.05
0.44
0.15
0.22
0.39
0.92
0.23
0.41
0.86
0.99
0.46
no. in subgroup 
Primary Outcome Death from Cardiovascular Causes
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ratios for cardiovascular outcomes. Thus, in 
clinical practice, the choice of the empaglif lozin 
dose will probably depend primarily on the 
achievement of metabolic targets and the occur-
rence of adverse events.
These benefits were observed in a population 
with established cardiovascular disease in whom 
cardiovascular risk factors, including blood pres-
sure and dyslipidemia, were well treated with the 
use of renin–angiotensin–aldosterone system in-
hibitors, statins, and acetylsalicylic acid. The 
reductions in the risk of cardiovascular death in 
the empagliflozin group were consistent across 
subgroups according to baseline characteristics.
Notably, reductions in the risks of death from 
cardiovascular causes and from any cause oc-
curred early in the trial, and these benefits con-
tinued throughout the study. The relative reduc-
tion of 32% in the risk of death from any cause 
in the pooled empagliflozin group means that 
39 patients (41 in the 10-mg group and 38 in the 
25-mg group) would need to be treated during a 
3-year period to prevent one death, but these 
numbers cannot be extrapolated to patient pop-
ulations with other clinical characteristics.
Even though investigators were encouraged to 
adjust glucose-lowering therapy according to local 
guidelines, many patients did not reach their 
glycemic targets, with an adjusted mean glycated 
hemoglobin level at week 206 of 7.81% in the 
pooled empagliflozin group and 8.16% in the 
Figure 3. Glycated Hemoglobin Levels.
Shown are mean (±SE) glycated hemoglobin levels in the three study groups, as calculated with the use of a repeat-
ed-measures analysis as a mixed model of all data for patients who received at least one dose of a study drug and 
had a baseline measurement. The model included baseline glycated hemoglobin as a linear covariate, with baseline 
estimated glomerular filtration rate, geographic region, body-mass index, the last week a patient could have had a 
glycated hemoglobin measurement, study group, visit, visit according to treatment interaction, and baseline glycat-
ed hemoglobin according to visit interaction as fixed effects.
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Figure 2 (facing page). Subgroup Analyses for the Primary 
Outcome and Death from Cardiovascular Causes.
Shown are the results of a prespecified Cox regression 
analysis of data for subgroups of patients with respect 
to the primary outcome. Subgroup analyses of death 
from cardiovascular causes were conducted post hoc. 
P values are for tests of homogeneity of between-group 
differences among subgroups with no adjustment for 
multiple testing. The size of the ovals is proportional 
to the number of patients in the subgroup. ACE denotes 
angiotensin-converting enzyme, ARB angiotensin-recep-
tor blocker, DBP diastolic blood pressure, and SBP sys-
tolic blood pressure.
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placebo group. Our trial was designed to assess 
the specific effects of empagliflozin on clinical 
outcomes, and the mechanisms behind the ob-
served benefits are speculative. As such, we infer 
that the mechanisms behind the cardiovascular 
benefits of empagliflozin are multidimensional25 
and possibly involve changes in arterial stiff-
ness,26,27 cardiac function, and cardiac oxygen 
Event
Placebo 
(N = 2333)
Empagliflozin,  
10 mg 
 (N = 2345)
Empagliflozin,  
25 mg 
 (N = 2342)
Pooled 
 Empagliflozin 
(N = 4687)
number of patients (percent)
Any adverse event 2139 (91.7) 2112 (90.1) 2118 (90.4) 4230 (90.2)†
Severe adverse event 592 (25.4) 536 (22.9) 564 (24.1) 1100 (23.5)‡
Serious adverse event
Any 988 (42.3) 876 (37.4) 913 (39.0) 1789 (38.2)†
Death 119 (5.1) 97 (4.1) 79 (3.4) 176 (3.8)§
Adverse event leading to discontinuation of a 
study drug
453 (19.4) 416 (17.7) 397 (17.0) 813 (17.3)§
Confirmed hypoglycemic 
 adverse event¶
Any 650 (27.9) 656 (28.0) 647 (27.6) 1303 (27.8)
Requiring assistance 36 (1.5) 33 (1.4) 30 (1.3) 63 (1.3)
Event consistent with urinary tract infection‖ 423 (18.1) 426 (18.2) 416 (17.8) 842 (18.0)
Male patients 158 (9.4) 180 (10.9) 170 (10.1) 350 (10.5)
Female patients 265 (40.6) 246 (35.5) 246 (37.3) 492 (36.4)‡
Complicated urinary tract infection** 41 (1.8) 34 (1.4) 48 (2.0) 82 (1.7)
Event consistent with genital infection†† 42 (1.8) 153 (6.5) 148 (6.3) 301 (6.4)†
Male patients 25 (1.5) 89 (5.4) 77 (4.6) 166 (5.0)†
Female patients 17 (2.6) 64 (9.2) 71 (10.8) 135 (10.0)†
Event consistent with volume depletion‡‡ 115 (4.9) 115 (4.9) 124 (5.3) 239 (5.1)
Acute renal failure§§ 155 (6.6) 121 (5.2) 125 (5.3) 246 (5.2)§
Acute kidney injury 37 (1.6) 26 (1.1) 19 (0.8) 45 (1.0)‡
Diabetic ketoacidosis¶¶ 1 (<0.1) 3 (0.1) 1 (<0.1) 4 (0.1)
Thromboembolic event§§ 20 (0.9) 9 (0.4) 21 (0.9) 30 (0.6)
Bone fracture‖‖ 91 (3.9) 92 (3.9) 87 (3.7) 179 (3.8)
*  Data are for patients who had one or more event and who had received at least one dose of a study drug. All events occurred within 7 days 
after the last receipt of the study drug.
†  P<0.001 for the comparison with placebo.
‡  P<0.05 for the comparison with placebo.
§  P<0.01 for the comparison with placebo.
¶  A confirmed hypoglycemic adverse event was a plasma glucose level of less than 70 mg per deciliter (3.9 mmol per liter) or an event re-
quiring assistance.
‖  The definition of urinary tract infection was based on 79 preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA). 
Percentages were calculated as the proportions of all men and all women with the event.
**  Complicated urinary tract infection was defined as pyelonephritis, urosepsis, or a serious adverse event consistent with urinary tract infection. 
A breakdown of such events according to MedDRA preferred terms is provided in Table S13 in Section R in the Supplementary Appendix.
††  The definition of genital infection was based on 88 MedDRA preferred terms. Percentages were calculated as the proportions of all men 
and all women with the event.
‡‡  The definition of volume depletion was based on 8 MedDRA preferred terms.
§§  The definitions of acute renal failure and thromboembolic event were based on 1 standardized MedDRA query for each.
¶¶  The definition of ketoacidosis was based on 4 MedDRA preferred terms.
‖‖  The definition of bone fracture was based on 62 MedDRA preferred terms.
Table 2. Adverse Events.*
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demand (in the absence of sympathetic-nerve 
activation),26 as well as cardiorenal effects,21,26,28,29 
reduction in albuminuria,20,30 reduction in uric 
acid,13-20 and established effects on hyperglycemia, 
weight, visceral adiposity, and blood pressure.13-20
Our trial provides data to support the long-
term use of empagliflozin, as well as strong evi-
dence for a reduction in cardiovascular risk. As 
observed in previous trials, genital infection was 
more common in patients treated with empa-
gliflozin. Urosepsis was infrequent but reported 
in more patients treated with empagliflozin, al-
though there was no increase in the overall rate 
of urinary tract infection, complicated urinary 
tract infection, or pyelonephritis. The proportions 
of patients with diabetic ketoacidosis, volume 
depletion, thromboembolic events, and bone 
fracture were low (ranging from <1% for keto-
acidosis and thromboembolic events to 5% for 
volume depletion) and similar in the empa-
glif lozin groups and the placebo group. Concern 
has been expressed about the renal safety of in-
hibitors of sodium–glucose cotransporter 2 over 
time. However, the percentage of patients with 
acute renal failure (including acute kidney injury) 
was lower in the empagliflozin groups than in 
the placebo group, and renal function was main-
tained with empagliflozin.
In conclusion, patients with type 2 diabetes at 
high risk for cardiovascular events who received 
empagliflozin had significantly lower rates of 
the primary composite cardiovascular outcome 
and of death from any cause than did those in 
the placebo group when the study drugs were 
added to standard care.
Supported by Boehringer Ingelheim and Eli Lilly.
Dr. Zinman reports receiving consulting fees from Merck, 
Novo Nordisk, Sanofi Aventis, Eli Lilly, Takeda, AstraZeneca, 
and Janssen and grant support through his institution from 
Merck and Novo Nordisk; Dr. Wanner, receiving grant support 
from the European Foundation of Studies in Diabetes–Boeh-
ringer Ingelheim European Diabetes Research Programme; 
Dr. Lachin, receiving fees for serving on a steering committee 
from Merck, fees for serving on data monitoring committees 
from Gilead, Janssen, and Novartis, and consulting fees from 
AstraZeneca; Dr. Fitchett, receiving fees for serving on a data 
and safety monitoring board from Novo Nordisk and consult-
ing fees from AstraZeneca, Sanofi, and Merck; Drs. Bluhmki, 
Hantel, Johansen, Woerle, and Broedel and Ms. Mattheus, be-
ing employees of Boehringer Ingelheim; and Dr. Inzucchi, re-
ceiving fees for serving on advisory boards from Merck, Jans-
sen, Sanofi/Regeneron, Poxel, Boehringer Ingelheim, and Eli 
Lilly, fees for serving on data monitoring committees from 
Novo Nordisk and Intarcia, fees for serving on a steering com-
mittee from Lexicon, serving as an expert witness on behalf of 
Takeda in a patent suit, and receiving clinical-study drugs 
from Takeda, and receiving funding through his institution 
from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Abbott, 
Merck, and Sanofi. No other potential conflict of interest rel-
evant to this article was reported.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients who participated in this trial and Eliza-
beth Ng and Wendy Morris of Fleishman-Hillard Group for their 
assistance in medical writing.
References
1. Sarwar N, Gao P, Seshasai SR, et al. 
Diabetes mellitus, fasting blood glucose 
concentration, and risk of vascular dis-
ease: a collaborative meta-analysis of 102 
prospective studies. Lancet 2010; 375: 
2215-22.
2. Beckman JA, Creager MA, Libby P. 
Diabetes and atherosclerosis: epidemiol-
ogy, pathophysiology, and management. 
JAMA 2002; 287: 2570-81.
3. Di Angelantonio E, Kaptoge S, Worm-
ser D, et al. Association of cardiometa-
bolic multimorbidity with mortality. JAMA 
2015; 314: 52-60.
4. Green JB, Bethel MA, Armstrong PW, 
et al. Effect of sitagliptin on cardiovascu-
lar outcomes in type 2 diabetes. N Engl J 
Med 2015; 373: 232-42 
5. White WB, Cannon CP, Heller SR, et al. 
Alogliptin after acute coronary syndrome 
in patients with type 2 diabetes. N Engl J 
Med 2013; 369: 1327-35.
6. Scirica BM, Bhatt DL, Braunwald E, et 
al. Saxagliptin and cardiovascular out-
comes in patients with type 2 diabetes 
mellitus. N Engl J Med 2013; 369: 1317-26.
7. Holman RR, Paul SK, Bethel MA, 
Matthews DR, Neil HA. 10-Year follow-up 
of intensive glucose control in type 2 dia-
betes. N Engl J Med 2008; 359: 1577-89.
8. Udell JA, Cavender MA, Bhatt DL, 
Chatterjee S, Farkouh ME, Scirica BM. 
Glucose-lowering drugs or strategies and 
cardiovascular outcomes in patients with 
or at risk for type 2 diabetes: a meta-analy-
sis of randomised controlled trials. Lan-
cet Diabetes Endocrinol 2015; 3: 356-66.
9. Department of Health and Human 
Services, Food and Drug Administration. 
Guidance for industry: diabetes mellitus 
— evaluating cardiovascular risk in new 
antidiabetic therapies to treat type 2 diabe-
tes (http://www .fda .gov/ downloads/ drugs/ 
guidancecomplianceregulatoryinformation/ 
guidances/ ucm071627 .pdf) .
10. Gallo LA, Wright EM, Vallon V. Prob-
ing SGLT2 as a therapeutic target for dia-
betes: basic physiology and consequences. 
Diab Vasc Dis Res 2015; 12: 78-89.
11. Grempler R, Thomas L, Eckhardt M, 
et al. Empaglif lozin, a novel selective 
 sodium glucose cotransporter-2 (SGLT-2) 
inhibitor: characterisation and compari-
son with other SGLT-2 inhibitors. Diabe-
tes Obes Metab 2012; 14: 83-90.
12. Boehringer Ingelheim Pharmaceuti-
cals. Jardiance (empaglif lozin) tablets; 
prescribing information (http://bidocs 
.boehringer-ingelheim .com/ BIWebAccess/ 
ViewServlet .ser?docBase=renetnt&folder 
Path=/ Prescribing+Information/ PIs/ 
Jardiance/ jardiance .pdf) .
13. Häring HU, Merker L, Seewaldt-Beck-
er E, et al. Empagliflozin as add-on to 
metformin plus sulfonylurea in patients 
with type 2 diabetes: a 24-week, random-
ized, double-blind, placebo-controlled 
trial. Diabetes Care 2013; 36: 3396-404.
14. Häring HU, Merker L, Seewaldt-Beck-
er E, et al. Empagliflozin as add-on to 
metformin in patients with type 2 diabe-
tes: a 24-week, randomized, double-blind, 
placebo-controlled trial. Diabetes Care 
2014; 37: 1650-9.
15. Kovacs CS, Seshiah V, Swallow R, et 
al. Empagliflozin improves glycaemic and 
weight control as add-on therapy to pio-
glitazone or pioglitazone plus metformin 
in patients with type 2 diabetes: a 24-week, 
randomized, placebo-controlled trial. Dia-
betes Obes Metab 2014; 16: 147-58.
16. Roden M, Weng J, Eilbracht J, et al. 
Empaglif lozin monotherapy with sita-
gliptin as an active comparator in pa-
The New England Journal of Medicine 
Downloaded from nejm.org on November 1, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;22 nejm.org November 26, 20152128
Empagliflozin in Type 2 Diabetes
tients with type 2 diabetes: a randomised, 
double-blind, placebo-controlled, phase 3 
trial. Lancet Diabetes Endocrinol 2013; 1: 
208-19.
17. Rosenstock J, Jelaska A, Frappin G, 
et al. Improved glucose control with 
weight loss, lower insulin doses, and no 
increased hypoglycemia with empagliflozin 
added to titrated multiple daily injections 
of insulin in obese inadequately con-
trolled type 2 diabetes. Diabetes Care 
2014; 37: 1815-23.
18. Rosenstock J, Jelaska A, Zeller C, Kim G, 
Broedl UC, Woerle HJ. Impact of empa-
gliflozin added on to basal insulin in type 
2 diabetes inadequately controlled on basal 
insulin: a 78-week randomized, double-
blind, placebo-controlled trial. Diabetes 
Obes Metab 2015 June 4 (Epub ahead of 
print).
19. Tikkanen I, Narko K, Zeller C, et al. 
Empagliflozin reduces blood pressure in 
patients with type 2 diabetes and hyper-
tension. Diabetes Care 2015; 38: 420-8.
20. Barnett AH, Mithal A, Manassie J, et al. 
Efficacy and safety of empagliflozin add-
ed to existing antidiabetes treatment in 
patients with type 2 diabetes and chronic 
kidney disease: a randomised, double-
blind, placebo-controlled trial. Lancet Dia-
betes Endocrinol 2014; 2: 369-84.
21. Chilton RC, Tikkanen I, Cannon CP, 
et al. Effects of empagliflozin on blood 
pressure and markers of arterial stiffness 
and vascular resistance in patients with 
type 2 diabetes. Diabetes Obes Metab 
2014 September 7 (Epub ahead of print).
22. Ridderstråle M, Andersen KR, Zeller 
C, Kim G, Woerle HJ, Broedl UC. Com-
parison of empagliflozin and glimepiride 
as add-on to metformin in patients with 
type 2 diabetes: a 104-week randomised, 
active-controlled, double-blind, phase 3 
trial. Lancet Diabetes Endocrinol 2014; 2: 
691-700.
23. Zinman B, Inzucchi SE, Lachin JM, 
et al. Rationale, design, and baseline char-
acteristics of a randomized, placebo-con-
trolled cardiovascular outcome trial of 
empagliflozin (EMPA-REG OUTCOME). 
Cardiovasc Diabetol 2014; 13: 102.
24. Beyersmann J, Allignol A, Schumacher 
M. Competing risks and multistate mod-
els with R. New York: Springer, 2011.
25. Inzucchi SE, Zinman B, Wanner C, et al. 
SGLT-2 inhibitors and cardiovascular risk: 
proposed pathways and review of ongoing 
outcome trials. Diab Vasc Dis Res 2015; 
12: 90-100.
26. Cherney DZ, Perkins BA, Soleyman-
lou N, et al. The effect of empagliflozin 
on arterial stiffness and heart rate vari-
ability in subjects with uncomplicated 
type 1 diabetes mellitus. Cardiovasc Dia-
betol 2014; 13: 28.
27. Cardoso CR, Ferreira MT, Leite NC, 
Salles GF. Prognostic impact of aortic stiff-
ness in high-risk type 2 diabetic patients: 
the Rio de Janeiro Type 2 Diabetes Cohort 
Study. Diabetes Care 2013; 36: 3772-8.
28. Ronco C, McCullough P, Anker SD, 
et al. Cardio-renal syndromes: report from 
the consensus conference of the Acute Di-
alysis Quality Initiative. Eur Heart J 2010; 
31: 703-11.
29. Cherney DZ, Perkins BA, Soleyman-
lou N, et al. Renal hemodynamic effect of 
sodium-glucose cotransporter 2 inhibi-
tion in patients with type 1 diabetes mel-
litus. Circulation 2014; 129: 587-97.
30. Bakris GL, Molitch M. Microalbumin-
uria as a risk predictor in diabetes: the con-
tinuing saga. Diabetes Care 2014; 37: 867-75.
Copyright © 2015 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org on November 1, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
